Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
CTI, Mahzi Therapeutics, and the Pitt Hopkins Research Foundation Announce Collaboration for Clinical Development in Pitt Hopkins Syndrome